Industry / Germany
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
G-BA's Decision Not To Reimburse Plavix Will Stand
April 2008 | Industry NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Germany's Federal Joint Committee on Healthcare (G-BA) has confirmed that it will not reimburse Plavix (clopidogrel) as a prophylactic treatment for cardiovascular disease. The decision comes as a result of findings by the Institute for Quality and Efficiency in Healthcare (IQWiG) in 2007 that Plavix had no real benefit over Aspirin when used as secondary